Table 1.
Details of Trials Included in the Meta-Analysis – 14 patients in AML15 aged <15 years are excluded from this meta-analysis. All trials excluded APL, and required no previous treatment.
| Trial | Dates of recruitment |
Number of patients included |
Eligibility criteria |
Median age of included patients (range) |
Cytogenetic grouping (MRC 2009)* |
Chemotherapy given |
Dose/schedule of GO |
Median follow- up for survival |
Last follow- up (publication) |
Last follow- up (meta- analysis) |
|---|---|---|---|---|---|---|---|---|---|---|
| MRC AML15 | 2002-2006 | 1099 | AML, either de Novo or secondary. Usually aged <60 | 50 (15-71) | Fav: 133(15%) Int: 565 (63%) Adv: 196 (22%) Unk: 205 |
DA (3+10, 3+8) or ADE (3+10+5, 3+8+5) or FLAG-Ida | 3mg/m2 on day 1 of chemotherapy | 86.0 months | January 2009 | March 2013 |
| SWOG-0106 | 2004-2009 | 595 | De Novo AML. Aged 18-60 | 47 (18-60) | Fav: 72 (17%) Int: 283 (67%) Adv: 67 (16%) Unk: 173 |
DA (3+7) + G-CSF/GM-CSF | 6mg/m2 on day 4 of chemotherapy | 55.2 months | February 2013 | June 2013 |
| NCRI AML16 | 2006-2010 | 1115 | AML, either de Novo or Secondary or high risk MDS. Usually aged 60+ | 67 (51-84) | Fav: 33(4%) Int: 576 (66%) Adv: 264 (30%) Unk: 242 |
DA (3+10, 3+8) or Daunorubicin (d,1,3, 5)/Clofarabine (d 1-5) | 3mg/m2 on day 1 of chemotherapy | 45.5 months | July 2011 | March 2013 |
| GOELAMS AML2006IR | 2007-2010 | 238 | De Novo AML, aged 18-60 | 50.5 (18-60) | Fav: 0 (0%) Int: 224 (100%) Adv: 0 (0%) Unk: 14 |
DA (3+7) | 6mg/m2 on day 4 of chemotherapy | 39.3 months | unpublished | January 2013 |
| ALFA-0701 | 2008-2010 | 278 | De Novo AML aged 50-70 | 62 (50-70) | Fav: 9 (4%) Int: 179 (73%) Adv: 57 (23%) Unk: 33 |
DA (3+7) | 3mg/m2 d 1,4,7 up to 5mg per dose | 24.1 months | August 2011 | August 2011 |
*
proportions exclude those with unknown or undetermined cytogenetics. All trials were open-label, centrally randomised and had OS as primary endpoint – thus viewed as at low risk of bias.